A systematic review of oral methotrexate for multiple sclerosis

  title={A systematic review of oral methotrexate for multiple sclerosis},
  author={Om Gray and G V McDonnell and Raeburn B Forbes},
  journal={Multiple Sclerosis},
  pages={507 - 510}
Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials identified, one was excluded due to its allocation concealment and definition of a relapse and time to sustained disease progression. The other trial studied 60 participants with progressive MS only… 

Tables from this paper

Progressive Multiple Sclerosis

None of the therapies currently approved for use in relapsing-remitting MS have been shown to slow the gradual progression of disability that occurs in the absence of recent relapses or changes in MRI.

High‐Dose Cyclophosphamide in the Treatment of Multiple Sclerosis

Results along with previous reports suggest that early use of HDC therapy in RRMS is promising, and HDC was well tolerated, demonstrated a good safety profile and had minimal adverse effects.

Disease-modifying agents in multiple sclerosis

  • P. Coyle
  • Medicine, Psychology
    Annals of Indian Academy of Neurology
  • 2009
This review will discuss the disease-modifying agents used currently in MS, as well as available alternative agents.

Immunosuppressive treatments in multiple sclerosis.

  • D. Okuda
  • Medicine, Biology
    Handbook of clinical neurology
  • 2014

Chemotherapeutics in the treatment of multiple sclerosis

The likely pathogenic mechanisms of multiple sclerosis provide a sound rationale for investigating the efficacy of drugs possessing immunosuppressive or immunomodulatory properties, and a thorough risk-benefit analysis is becoming increasingly important in the assessment of therapeutic options for this disabling disease.

Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.

The present paper translated an effort from representatives of eight countries discussing a matter that cannot be adapted to the authors' region directly from purely European and North-American guidelines for treatment.

Therapeutic Approaches to Multiple Sclerosis

This review summarizes trials on MS treatments since 2001 that failed or were interrupted, attempts to analyze the underlying reasons for failure, and discusses the implications for the current view of MS pathogenesis, clinical practice, and design of future studies.

Immunotherapy of Multiple Sclerosis

This review summarizes in detail the existing information on all the available immunotherapies for MS, classifies them according to their immunologic mechanisms of action and proposes a structured algorithm/therapeutic scheme for the management of the disease.

A narrative review of psoriasis and multiple sclerosis: links and risks

It is concluded that further study is necessary to discern whether there may be a significant relationship between PsO and MS, and clinicians may find it appropriate to screen for MS in patients with PsO, allowing for timely referral to a neurologist should it be necessary.

Management of multiple sclerosis in adolescents – current treatment options and related adherence issues

Multiple sclerosis (MS) is a progressive inflammatory demyelinating disorder of the central nervous system that is increasingly recognized in children and adolescents. This realization comes with



Methotrexate for multiple sclerosis.

BACKGROUND Methotrexate is a potent immunosuppressant which in theory could reduce relapse rates and delay disease progression in multiple sclerosis (MS). Subsequently, clinical trials of

Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis

It is concluded that low‐dose, weekly, oral methotrexate offers a new, relatively nontoxic treatment option for patients with chronic progressive MS.

Methotrexate hepatotoxicity: What is the evidence?

MTX has become the most commonly prescribed anti-rheumatic drug used in the treatment of RA and is well tolerated in the long term: data show that approximately 50% of patients are still taking MTX after 5 years of treatment.

Methotrexate: mechanism of action in rheumatoid arthritis.

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study.

An 18-month double-blind treatment of multiple sclerosis with low dose oral methotrexate showed it to be well tolerated and suggested effectiveness in exacerbating-remitting MS but not in the

The initiation of the autoimmune response in multiple sclerosis

New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

Today there is a need for more exact criteria than existed earlier in order to conduct therapeutic trials in multicenter programs, to compare epidemiological surveys, to evaluate new diagnostic procedures, and to estimate the activity of the disease process in MS.

Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate.

It is concluded that weekly oral MTX therapy in patients with active rheumatoid arthritis inhibits neutrophil 5-LO pathway product generation in a pattern consistent with inhibition of the activity of the 5- LO enzyme; an effect is observed after the first dose.

The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

Results indicate that methotrexate is a nonsteroidal antiinflammatory agent, the antiphlogistic action of which is due to increased adenosine release at inflamed sites.